This is an IRB-approved randomized-controlled trial. Patients with MS and LUTS were recruited and had 2 visits to our center. On the first visit, preliminary baseline demographics and disease characteristics were assessed including age, sex, BMI, Expanded disability Status Scale EDSS, duration of both MS and LUTS, type of MS (relapsing remitting RR, primary progressive PP, or secondary progressive SP), MS treatment, previous urological follow-up, and anterior urological treatment. Moreover, evaluation of symptoms using the OverActive Bladder Symptom Score (OABSS) and the voiding sub-score of the International Prostate Symptom Score (IPSS-V), bother caused by these symptoms using Urinary Bothersome Questionnaire in Multiple Sclerosis for voiding (UBQMS-V) and filling (UBQMS-F), and urologic quality of life using SF-QUALIVEEN [3], were evaluated. Patients also had urinalysis with urine culture, plasmatic creatinine level, and renal bladder ultrasound. On the second visit, patients were randomized in 2 groups: group A who underwent uroflowmetry, and group B who underwent uroflowmetry, cystomanometry, pressure flow study (PFS), and electromyography (EMG). After the diagnosis, a treatment was given to each patient based on the whole evaluation. The same physician was responsible of the interpretation of the urodynamic evaluation, making the diagnosis, and deciding about the treatment. Patients were then blindly phone called on the first, third and sixth months following treatment in order to evaluate their adherence to treatment, and any change in their urinary symptoms, bother, or urologic quality of life. These results were compared between the two groups before and after the initiation of treatment, using Mann Whitney’s test and Mood’s median test followed by a comparison of the results before and after the initiation of treatment independently of group using Wilcoxon’s test.